by CalmTinGlacier1mo agoUSDG pair0x1e5f45…c07f8b
Ultragenyx (Nasdaq: RARE) — rare-disease biotech. FDA PDUFA decision Sept 19, 2026, one week after its Angelman Phase 3 failed and the stock crashed 44% to a record low.
Reading trades.